Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years
Background: This phase 3, multi-center, open-label study evaluated the immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM, Menveo®; Novartis Vaccines and Diagnostics S.r.l., Siena, Italy) in healthy Indian subjects aged 2–75 years, to provide data for licensure...
Main Authors: | Sanjay Lalwani, Sharad Agarkhedkar, Nithya Gogtay, Sonali Palkar, Shalaka Agarkhedkar, Urmila Thatte, Hoshang Vakil, Rekha Jonnalagedda, Paola Pedotti, Margaret Hoyle, Chiranjiwi Bhusal, Ashwani Arora |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-09-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971215001708 |
Similar Items
-
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
by: Hoan Jong Lee, et al.
Published: (2014-11-01) -
Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review
by: Jessica Presa, et al.
Published: (2019-07-01) -
Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015–2016
by: Helen Campbell, et al.
Published: (2017-07-01) -
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) in Children 9–23 Months of Age in Russian Federation: Results of Russian Part of International Study in Russia and India
by: O. A. Perminova, et al.
Published: (2020-05-01) -
Different Long-Term Duration of Seroprotection against <i>Neisseria meningitidis</i> in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands
by: Milou Ohm, et al.
Published: (2020-10-01)